Ticker Details
Cue Biopharma, Inc. Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
IPO Date:	January 2, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$199.34M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.36 | 4.57%
Avg Daily Range (30 D):	$1.40 | 4.97%
Avg Daily Range (90 D):	$1.99 | 7.98%

Institutional Daily Volume
Avg Daily Volume:	.53M
Avg Daily Volume (30 D):	.15M
Avg Daily Volume (90 D):	.38M

Trade Size
Avg Trade Size (Sh.):	212
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	38

Institutional Trades
Total Institutional Trades:	195
Avg Institutional Trade:	$2.09M
Avg Institutional Trade (30 D):	$.69M
Avg Institutional Trade (90 D):	$1.03M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.1M
Avg Closing Trade (30 D):	$.69M
Avg Closing Trade (90 D):	$.77M
Avg Closing Volume:	9.38K

News

Jul 13, 2026 @ 5:00 PM Head and Neck Squamous Cell Carcinoma Market is Pr... Source: Na

Jul 10, 2026 @ 1:40 AM Cue Biopharma Announces $50.0 Million Private Plac... Source: Na

May 7, 2026 @ 11:07 PM Cue Biopharma Reports Inducement Grants Under Nasd... Source: Na

Apr 8, 2026 @ 12:00 PM Cue Biopharma to Receive $7.5 Million Preclinical ... Source: Na

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-28.43	$-24.14	$-1.08
Diluted EPS	$-28.43	$-24.14	$-1.08
Revenue	$37.65M	$7.88M	$5.69M
Gross Profit
Net Income / Loss	$-164.11M	$-153.07M	$-5.18M
Operating Income / Loss	$-98.67M	$-87.7M	$-5.35M
Cost of Revenue
Net Cash Flow	$-10.1M	$1.01M	$-10.76M
PE Ratio

Splits
Apr 24, 2026	1:30